Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

For 20 years, monoclonal antibodies (mAbs) have been a standard component of cancer
therapy, but there is still much room for improvement. Efforts continue to build better cancer …

Acute myeloid leukaemia (AML) is a disorder characterized by a clonal proliferation derived
from primitive haematopoietic stem cells or progenitor cells. Abnormal differentiation of …

Every year, more than 8000 new cases of chronic myeloid leukemia (CML) are diagnosed in
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …

Immunological control may contribute to achievement of deep molecular response in chronic
myeloid leukemia (CML) patients on tyrosine kinase inhibitor (TKI) therapy and may promote …

Antibody-based immunotherapy is a promising strategy for targeting chemoresistant
leukemic cells. However, classical antibody-based approaches are restricted to targeting …

CD19-directed chimeric antigen receptor (CAR) T cells are clinically effective in a limited set
of leukemia patients. However, CAR T-cell therapy thus far has been largely restricted to …

Intracellular tumor antigens presented on the cell surface in the context of human leukocyte
antigen (HLA) molecules have been targeted by T cell–based therapies, but there has been …

Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management
of chronic myeloid leukemia. Imatinib produces acceptable responses in approximately 60 …

Monoclonal antibodies are among the most clinically effective drugs used to treat cancer.
However, their target repertoire is limited as there are relatively few tumor-specific or tumor …